Relay Therapeutics, Inc. (RLAY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$18.66-2.35%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Increase revenue streams above $3 million quarterly: metric not reported.
Relay Therapeutics is advancing its drug zovegalisib to Phase 3 trials for breast cancer. Strong trial data supports this progress. The company aims to manage operating losses near negative $78.6 million in 2026-Q1. Revenue growth is critical after a recent drop to $3 million in 2026-Q1.
The company faces increasing operating losses and declining revenue. Competitive risks and recent litigation filings challenge its outlook. Continued losses and failure to advance key drugs could hurt the business.
The stock price is about 14% above our model's value estimate and 31% below the median analyst target. Analysts expect about 33% revenue growth. Our view is more cautious on revenue and loss management progress.
Breaks if: Phase 3 development not initiated by 2026-Q4
Continue Phase 3 development of zovegalisib in HR+/HER2- metastatic breast cancer and initiate frontline Phase 3 trial with atirmociclib triplet.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity focused on advancing clinical-stage therapies. The current thesis state indicates mixed progress in key trials, with management prioritizing multiple developments for zovegalisib.
The market appears to have priced in a low level of fragility, with a valuation that suggests a premium compared to peers. However, there is a notable expectations gap, indicating that the market may not fully account for the risks associated with its ongoing clinical trials.
Fundamentals are likely to remain weak in the near term, as the company reported significant net losses and declining momentum. Management's focus on advancing clinical trials is crucial, but the recent financial performance has not met industry standards.
The thesis hinges on several factors, including the outcomes of upcoming clinical trials and the overall performance of the healthcare sector. Additionally, any cuts to guidance or worsening economic indicators could negatively impact sentiment.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. H.C. Wainwright raised its estimate to $29 from $28. This suggests a higher valuation target and a specific full-year loss projection for 2026. The company ended Q2 with $910.9 million in cash, providing operational runway into 2029.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Management reiterated ongoing execution of the Phase 3 ReDiscover-2 trial and plans to initiate a Phase 3 frontline trial of zovegalisib plus atirmociclib in early 2027. The company reported $3.0M revenue in 2026-Q1 and net losses around $73M, consistent with clinical-stage development. The trajectory shows continued focus and execution on advancing zovegalisib to Phase 3 trials.
“Relay Tx continues to execute on the Phase 3 ReDiscover-2 trial of zovegalisib + fulvestrant in PI3Kα-mutated breast cancer.”
“Phase 3 1L trial in endocrine-sensitive breast cancer expected to initiate in early 2027, subject to regulatory feedback.”
“Continued execution of ongoing ReDiscover-2 Phase 3 trial in second line breast cancer.”
Breaks if: Quarterly revenue remains below $3 million by 2026-Q4
Breaks if: Operating loss worsens beyond negative $80 million next 4 quarters
Control operating expenses and net losses while advancing clinical programs.
Stated as a priority in 3 quarters including 2026-Q1, 2025-Q4, and 2025-Q3. The company reported net losses of $73.3M in 2026-Q1, $54.9M in 2025-Q4, and $74.1M in 2025-Q3, reflecting ongoing investment in clinical programs. Operating expenses remain high but relatively stable, indicating management is maintaining cost discipline while advancing development. The trajectory shows consistent management of operating losses.
“Operating expenses were $81.6 million and net loss was $73.3 million for the first quarter of 2026.”
“Operating income was negative $60.6 million and net income was negative $54.9 million for 2025-Q4.”
“Operating income was negative $80.4 million and net income was negative $74.1 million for 2025-Q3.”
Over the next 1 to 3 years, RLAY's trajectory will depend heavily on clinical execution and market conditions. Not investment advice.